Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-07-2016 | Oncology

Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height

Authors: Kishan Gupta, Colin A. McCannel, Mitchell Kamrava, James Lamb, Robert D. Almanzor, Tara A. McCannel

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 7/2016

Abstract

Purpose

To evaluate the relationship between choroidal melanoma regression rate and its gene expression profile class after iodine-125 brachytherapy at 3 and 6 months, controlling for baseline tumor height.

Methods

Patients from October 2012 to January 2015 at a single Ophthalmic Oncology Center who had undergone iodine-125 brachytherapy for the treatment of choroidal melanoma and who had a gene expression profile test result obtained from intraoperative fine-needle aspiration biopsy at the time of plaque surgery were retrospectively reviewed. Baseline patient and tumor characteristics were obtained, including tumor height and gene expression profile test result. Tumor height at 3 and 6 months following treatment was obtained. Regression rate was analyzed with two-way analysis of variance to class type and baseline pre-operative tumor height. Class 2 patients were matched to class 1 patients by tumor height and resulting distributions of paired regression rate differences were compared.

Results

A total of 114 patients were studied. When preoperative tumor height was controlled for in the comparative analysis, neither group of patients at 3 or 6 months had a significant dependency between gene expression profile class and tumor regression rate. Additionally, class 1 and class 2 patients matched for pre-operative tumor height did not express different regression rates.

Conclusions

Our study adds to a growing body of evidence that tumor regression rate does not necessarily depend on gene expression profile class type in choroidal melanoma after brachytherapy at 3 and 6 months when controlling for baseline tumor height.

Singh AD, Turell ME, Topham AK (2011) Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118:1881–1885. doi:10.1016/j.ophtha.2011.01.040 CrossRefPubMed

Augsburger JJ, Gamel JW, Shields JA et al (1987) Post-irradiation regression of choroidal melanomas as a risk factor for death from metastatic disease. Ophthalmology 94:1173–1177. doi:10.1016/S0161-6420(87)33310-X CrossRefPubMed

Glynn RJ, Seddon JM, Gragoudas ES et al (1989) Evaluation of tumor regression and other prognostic factors for early and late metastasis after proton irradiation of UVeal melanoma. Ophthalmology 96:1566–1573. doi:10.1016/S0161-6420(89)32685-6 CrossRefPubMed

Kaiserman I, Anteby I, Chowers I et al (2004) Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. Br J Ophthalmol 88:892–895. doi:10.1136/bjo.2003.036285 CrossRefPubMedPubMedCentral

Guthoff R, Haase J, von Domarus D et al (1990) The regression behavior of choroid melanoma following radiotherapy—a new prognostic parameter? Klin Monbl Augenheilkd 196:6–10. doi:10.1055/s-2008-1046119 CrossRefPubMed

Authors N (2006) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. Arch Ophthalmol 124:1684. doi:10.1001/archopht.124.12.1684 CrossRef

Prescher G, Bornfeld N, Hirche H et al (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222–1225CrossRefPubMed

Damato B, Duke C, Coupland SE et al (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114:1925–1931. doi:10.1016/j.ophtha.2007.06.012 CrossRefPubMed

Van Essen TH, van Pelt SI, Versluis M et al (2014) Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol 98:1738–1743. doi:10.1136/bjophthalmol-2014-305047 CrossRefPubMed

10.

Van den Bosch T, van Beek JGM, Vaarwater J et al (2012) Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci 53:2668–2674. doi:10.1167/iovs.11-8697 CrossRefPubMed

11.

Onken MD, Worley LA, Char DH et al (2012) Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 119:1596–1603. doi:10.1016/j.ophtha.2012.02.017 CrossRefPubMedPubMedCentral

12.

Harbour JW, Chen R (2013) The decisiondx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLoS Curr 12597007:1–10. doi:10.1371/currents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618

13.

Shields CL, Furuta M, Berman EL et al (2009) Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol 127:981–987. doi:10.1001/archophthalmol.2009.151 CrossRefPubMed

14.

Marathe OS, Wu J, Lee SP et al (2011) Ocular response of choroidal melanoma with monosomy 3 versus disomy 3 after iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 81:1046–1048. doi:10.1016/j.ijrobp.2010.07.016 CrossRefPubMed

15.

Chiam PJT, Coupland SE, Kalirai H et al (2014) Does choroidal melanoma regression correlate with chromosome 3 loss after ruthenium brachytherapy? Br J Ophthalmol 98:967–971. doi:10.1136/bjophthalmol-2013-304472 CrossRefPubMed

16.

Rao RC, Khan M, Badiyan SN, Harbour JW (2015) Gene expression profiling and regression rate of irradiated uveal melanomas. Ophthalmic Surg Lasers Imaging Retina 46:333–337. doi:10.3928/23258160-20150323-06 CrossRefPubMedPubMedCentral

17.

Chen RWS, Harbour JW (2014) Rapid regression of a subset of class 1 uveal melanomas after Iodine-125 plaque radiotherapy suggests an inflammatory mechanism. Graefes Arch Clin Exp Ophthalmol 252:2021–2022. doi:10.1007/s00417-014-2793-1 CrossRefPubMedPubMedCentral

18.

Corrêa ZM, Augsburger JJ (2014) Relationship between rate of posterior uveal melanoma flattening following plaque radiotherapy and gene expression profile class of tumor cells. Invest Ophthalmol Vis Sci 55:556–559. doi:10.1167/iovs.13-13381 CrossRefPubMed

19.

Demirci H, Saponara F, Khan A et al (2015) Regression rate of posterior uveal melanomas following iodine-125 plaque radiotherapy. Middle East Afr J Ophthalmol 22:103. doi:10.4103/0974-9233.148358 CrossRefPubMedPubMedCentral

20.

Chappell MC, Char DH, Cole TB et al (2012) Uveal melanoma: molecular pattern, clinical features, and radiation response. Am J Ophthalmol 154:227–232. doi:10.1016/j.ajo.2012.02.022 CrossRefPubMed

21.

Shields CL, Ganguly A, Materin MA et al (2007) Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. Trans Am Ophthalmol Soc 105:43–52, discussion 52–3PubMedPubMedCentral

22.

Onken MD, Worley LA, Dávila RM et al (2006) Prognostic testing in uveal melanoma by transcriptomic profiling of fine-needle biopsy specimens. J Mol Diagn 8:567–573. doi:10.2353/jmoldx.2006.060077 CrossRefPubMedPubMedCentral

23.

Faulkner-Jones BE, Foster WJ, Harbour JW et al (2005) Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. Acta Cytol 49:297–308CrossRefPubMed

24.

McCannel TA, Chang MY, Burgess BL (2012) Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma. Ophthalmology 119:606–610. doi:10.1016/j.ophtha.2011.08.046 CrossRefPubMed

25.

Simpson ER, Gallie B, Laperrierre N et al (2014) The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 13:1–14. doi:10.1016/j.brachy.2013.11.008 CrossRef

26.

Cruess AF, Augsburger JJ, Shields JA et al (1984) Regression of posterior uveal melanomas following cobalt-60 plaque radiotherapy. Ophthalmology 91:1716–1719CrossRefPubMed

27.

Rashid M, Heikkonen J, Kivelä T (2015) Tumor regression after brachytherapy for choroidal melanoma: reduction of thickness and cross-sectional area by shape and regression pattern. Invest Ophthalmol Vis Sci. doi:10.1167/iovs.14-16322 PubMedPubMedCentral

Title: Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height
Authors: Kishan Gupta
Colin A. McCannel
Mitchell Kamrava
James Lamb
Robert D. Almanzor
Tara A. McCannel
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-016-3305-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2016

Role of preoperative cycloplegic refraction in LASIK treatment of hyperopia

Serum prolidase activity and oxidative stress in patients with pseudoexfoliation syndrome

Analyzing biomechanical parameters of the cornea with glaucoma severity in open-angle glaucoma

Factors influencing the pupillary light reflex in healthy individuals

Split-cornea transplantation — a microbiologically safe approach?

Progression of primary open angle glaucoma in asymmetrically myopic eyes